Solid Biosciences ^Competitor

Solid Biosciences Inc. is a precision genetic medicine company based in Cambridge, MA, founded in 2013. The company is dedicated to developing gene therapies and genetic regulators for rare neuromuscular and cardiac diseases, with a strong focus on improving patient outcomes. Solid Biosciences prioritizes Duchenne muscular dystrophy (DMD) and has expanded its research to include Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and genetic cardiomyopathies.

The company’s key product, SGT-001, is a microdystrophin gene therapy aimed at delivering a functional dystrophin gene to muscle cells for DMD treatment. Solid Biosciences also works on gene therapies for Friedreich’s ataxia and CPVT, alongside developing innovative delivery platforms and genetic regulators to enhance therapy efficacy. The company engages with patient communities and collaborates with academic institutions and biotech partners to advance its research and clinical programs.